http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104739881-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-747 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-742 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-744 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00 |
| filingDate | 2015-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-104739881-B |
| titleOfInvention | A kind of compound lactobacillus acidophilus preparation method of granules of high viability |
| abstract | The invention discloses a kind of compound lactobacillus acidophilus preparation method of granules of high viability, are tentatively included using low boiling point volatile oil, low temperature spray drying, protect compound lactobacillus acidophilus activity, and then include using polyacrylic resin I number, high-boiling granulation.The present invention has focused on solving the low problem of lactobacillus acidophilus survival rate, it is tentatively included using low boiling point volatile oil, and it volatilizees at a high temperature of boiling granulating, while to realize that lactobacillus acidophilus is not, usually, thermically destroyed, realize that the secondary inclusion of Eudragit, the Eudragit lactobacillus acidophilus inclusion compound of formation do not decompose in gastric juice, but it is decomposed when reaching in enteron aisle and is adhered to intestinal wall surface, biological containment effect is played, pathogenic bacteria are blocked, therapeutic effect is played.Simultaneously as improving the survival rate of compound lactobacillus acidophilus, therefore dose is made to reduce by 5 times or more, reduce adverse reaction, increases applicability of the patient to drug.Raw materials for production cost can be effectively reduced. |
| priorityDate | 2015-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 43.